BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34198757)

  • 1. Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.
    Watanabe A; Miyake K; Akahane K; Goi K; Kagami K; Yagita H; Inukai T
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34198757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
    Akahane K; Inukai T; Zhang X; Hirose K; Kuroda I; Goi K; Honna H; Kagami K; Nakazawa S; Endo K; Kubota T; Yagita H; Koyama-Okazaki T; Sugita K
    Exp Hematol; 2010 Oct; 38(10):885-95. PubMed ID: 20670671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.
    Zhang X; Inukai T; Hirose K; Akahane K; Kuroda I; Honna-Oshiro H; Kagami K; Goi K; Nakamura K; Kobayashi M; Endo M; Yagita H; Kurosawa H; Thomas Look A; Honda H; Inaba T; Nakazawa S; Sugita K
    Leukemia; 2012 Dec; 26(12):2483-93. PubMed ID: 22743623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
    Kuroda I; Inukai T; Zhang X; Kikuchi J; Furukawa Y; Nemoto A; Akahane K; Hirose K; Honna-Oshiro H; Goi K; Kagami K; Yagita H; Tauchi T; Maeda Y; Sugita K
    Oncogene; 2013 Mar; 32(13):1670-81. PubMed ID: 22665066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
    Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
    Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of TRAIL resistance by radiation-induced hypermethylation of DR4 CpG island in recurrent laryngeal squamous cell carcinoma.
    Lee JC; Lee WH; Min YJ; Cha HJ; Han MW; Chang HW; Kim SA; Choi SH; Kim SW; Kim SY
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1203-11. PubMed ID: 24661673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
    Elias A; Siegelin MD; Steinmüller A; von Deimling A; Lass U; Korn B; Mueller W
    Clin Cancer Res; 2009 Sep; 15(17):5457-65. PubMed ID: 19706813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DR4-Ser424
    Lee H; Oh Y; Jeon YJ; Lee SY; Kim H; Lee HJ; Jung YK
    Cancer Res; 2019 Jun; 79(11):2839-2852. PubMed ID: 30987996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death receptor 5 is activated by fucosylation in colon cancer cells.
    Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
    FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.
    Aguilera DG; Das CM; Sinnappah-Kang ND; Joyce C; Taylor PH; Wen S; Hasselblatt M; Paulus W; Fuller G; Wolff JE; Gopalakrishnan V
    J Neurooncol; 2009 Jul; 93(3):303-18. PubMed ID: 19148581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
    Bae SI; Cheriyath V; Jacobs BS; Reu FJ; Borden EC
    Oncogene; 2008 Jan; 27(4):490-8. PubMed ID: 17653094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
    Milutinovic S; Kashyap AK; Yanagi T; Wimer C; Zhou S; O'Neil R; Kurtzman AL; Faynboym A; Xu L; Hannum CH; Diaz PW; Matsuzawa S; Horowitz M; Horowitz L; Bhatt RR; Reed JC
    Mol Cancer Ther; 2016 Jan; 15(1):114-24. PubMed ID: 26516157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
    Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
    J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
    Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
    Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
    Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks.
    Bertram H; Nerlich A; Omlor G; Geiger F; Zimmermann G; Fellenberg J
    Mod Pathol; 2009 Jul; 22(7):895-905. PubMed ID: 19305384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
    Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ
    J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.
    Nathwani SM; Greene LM; Butini S; Campiani G; Williams DC; Samali A; Szegezdi E; Zisterer DM
    Int J Oncol; 2016 Jul; 49(1):74-88. PubMed ID: 27176505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.